Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 3.38M
2: EX-10.1 Material Contract HTML 43K
3: EX-10.2 Material Contract HTML 34K
4: EX-12 Statement re: Computation of Ratios HTML 60K
5: EX-15 Letter re: Unaudited Interim Financial Information HTML 44K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 41K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 41K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 36K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 36K
83: R1 Document and Entity Information HTML 64K
63: R2 Consolidated Statements of Financial Condition HTML 188K
78: R3 Consolidated Statements of Financial Condition HTML 127K
(Parenthetical)
87: R4 Consolidated Statements of Income HTML 196K
111: R5 Consolidated Statements of Comprehensive Income HTML 89K
66: R6 Consolidated Statements of Cash Flows HTML 197K
77: R7 Consolidated Statements of Changes in Total Equity HTML 99K
57: R8 Introduction and Basis of Presentation HTML 63K
46: R9 Significant Accounting Policies HTML 47K
113: R10 Fair Value Disclosures HTML 1.10M
89: R11 Investment Securities HTML 291K
88: R12 Collateralized Transactions HTML 107K
95: R13 Variable Interest Entities and Securitization HTML 282K
Activities
96: R14 Loans and Allowance for Loan Losses HTML 293K
93: R15 Deposits HTML 56K
97: R16 Long-Term Borrowings and Other Secured Financings HTML 59K
79: R17 Derivative Instruments and Hedging Activities HTML 579K
84: R18 Commitments, Guarantees and Contingencies HTML 160K
91: R19 Regulatory Requirements HTML 123K
122: R20 Total Equity HTML 119K
106: R21 Earnings Per Common Share HTML 79K
72: R22 Interest Income and Interest Expense HTML 62K
90: R23 Employee Benefit Plans HTML 49K
75: R24 Income Taxes HTML 47K
36: R25 Segment and Geographic Information HTML 145K
107: R26 Equity Method Investments HTML 49K
117: R27 Subsequent Events HTML 49K
51: R28 Significant Accounting Policies (Policy) HTML 43K
50: R29 Fair Value Disclosures (Tables) HTML 1.06M
55: R30 Investment Securities (Tables) HTML 279K
56: R31 Collateralized Transactions (Tables) HTML 92K
58: R32 Variable Interest Entities and Securitization HTML 232K
Activities (Tables)
25: R33 Loans and Allowance for Loan Losses (Tables) HTML 267K
104: R34 Deposits (Tables) HTML 46K
70: R35 Long-Term Borrowings and Other Secured Financings HTML 53K
(Tables)
73: R36 Derivative Instruments and Hedging Activities HTML 534K
(Tables)
41: R37 Commitments, Guarantees and Contingencies (Tables) HTML 105K
120: R38 Regulatory Requirements (Tables) HTML 86K
16: R39 Total Equity (Tables) HTML 99K
60: R40 Earnings Per Common Share (Tables) HTML 77K
110: R41 Interest Income and Interest Expense (Tables) HTML 61K
38: R42 Employee Benefit Plans (Tables) HTML 46K
49: R43 Segment and Geographic Information (Tables) HTML 139K
54: R44 Introduction and Basis of Presentation (Details) HTML 40K
64: R45 Fair Value Disclosures (Assets and Liabilities HTML 639K
Measured at Fair Value on a Recurring Basis)
(Details)
24: R46 Fair Value Disclosures (Changes in Level 3 Assets HTML 1.06M
and Liabilities Measured at Fair Value on a
Recurring Basis) (Details)
45: R47 Fair Value Disclosures (Quantitative Information HTML 677K
about and Sensitivity of Significant Unobservable
Inputs Used in Recurring Level 3 Fair Value
Measurements) (Details)
18: R48 Fair Value Disclosures (Fair Value of Investments HTML 108K
that Calculate Net Asset Value) (Details)
109: R49 Fair Value Disclosures (Net Gains (Losses) Due to HTML 76K
Changes in Fair Value for Items Measured at Fair
Value Pursuant to the Fair Value Option Election)
(Details)
37: R50 Fair Value Disclosures (Short-term and Long-term HTML 51K
Borrowings) (Details)
105: R51 Fair Value Disclosures (Gains (Losses) Due to HTML 47K
Changes in Instrument Specific Credit Risk)
(Details)
42: R52 Fair Value Disclosures (Net Difference between HTML 51K
Contractual Principal Amount and Fair Value)
(Details)
61: R53 Fair Value Disclosures (Assets Measured at Fair HTML 151K
Value on a Nonrecurring Basis) (Details)
17: R54 Fair Value Disclosures (Financial Instruments Not HTML 215K
Measured at FV) (Details)
21: R55 Investment Securities (Schedule of Investment HTML 243K
Securities) (Details)
53: R56 Investment Securities (Schedule of Investment HTML 189K
Securities in an Unrealized Loss Position)
(Details)
29: R57 Investment Securities (Schedule of Amortized Cost HTML 265K
and Fair Value of Available for Sale Debt
Securities by Contractual Date) (Details)
114: R58 Investment Securities (Schedule of Proceeds of HTML 42K
Sale of Securities Available for Sale) (Details)
68: R59 Collateralized Transactions (Narrative) (Details) HTML 46K
94: R60 Collateralized Transactions (Balance Sheet HTML 119K
Offsetting) (Details)
44: R61 Collateralized Transactions (Financial Instruments HTML 54K
Owned That Have Been Loaned Or Pledged To
Counterparties) (Details)
47: R62 Collateralized Transactions (Cash And Securities HTML 44K
Deposited With Clearing Organizations Or
Segregated Under Federal And Other Regulations Or
Requirements) (Details)
102: R63 Variable Interest Entities and Securitization HTML 74K
Activities (Narrative) (Details)
98: R64 Variable Interest Entities and Securitization HTML 57K
Activities (Consolidated VIEs) (Details)
71: R65 Variable Interest Entities and Securitization HTML 182K
Activities (Non-Consolidated VIEs) (Details)
100: R66 Variable Interest Entities and Securitization HTML 133K
Activities (Transfers of Assets with Continuing
Involvement 1) (Details)
43: R67 Variable Interest Entities and Securitization HTML 119K
Activities (Transfers of Assets with Continuing
Involvement 2) (Details)
76: R68 Variable Interest Entities and Securitization HTML 56K
Activities (Failed Sales) (Details)
116: R69 Variable Interest Entities and Securitization HTML 38K
Activities (Mortgage Servicing Activities)
(Details)
20: R70 Loans and Allowance for Loan Losses (Outstanding HTML 175K
Loans and Credit Quality) (Details)
35: R71 Loans and Allowance for Loan Losses (Impaired HTML 104K
Loans) (Details)
62: R72 Loans and Allowance for Loan Losses (Loans and HTML 232K
Lending-related Commitments) (Details)
27: R73 Loans and Allowance for Loan Losses (Employee HTML 52K
Loans) (Details)
119: R74 Deposits (Details) HTML 74K
39: R75 Long-Term Borrowings and Other Secured Financings HTML 43K
(Other Narratives) (Details)
30: R76 Long-Term Borrowings and Other Secured Financings HTML 52K
(Long-term Borrowings) (Details)
34: R77 Long-Term Borrowings and Other Secured Financings HTML 49K
(Other Secured Financings) (Details)
22: R78 Derivative Instruments and Hedging Activities HTML 79K
(Other Disclosures) (Details)
26: R79 Derivative Instruments and Hedging Activities HTML 144K
(Components of Derivative Products) (Details)
85: R80 Derivative Instruments and Hedging Activities HTML 109K
(Fair Value of OTC Derivatives in a Gain Position)
(Details)
32: R81 Derivative Instruments and Hedging Activities HTML 446K
(Fair Value of Derivative Instruments Designated
and Not Designated as Accounting Hedges by Type of
Derivative Contract on a Gross Basis) (Details)
115: R82 Derivative Instruments and Hedging Activities HTML 78K
(Gains or Losses on Derivative Instruments,
Related Hedge Items and Hedge Ineffectiveness)
(Details)
59: R83 Derivative Instruments and Hedging Activities HTML 301K
(Notional and Fair Value of Protection Sold and
Purchased through Credit Default Swaps) (Details)
92: R84 Commitments, Guarantees and Contingencies HTML 131K
(Narrative - Contingencies) (Details)
99: R85 Commitments, Guarantees and Contingencies HTML 107K
(Commitments) (Details)
31: R86 Commitments, Guarantees and Contingencies HTML 143K
(Obligations under Guarantee Arrangements)
(Details)
33: R87 Regulatory Requirements (Narrative) (Details) HTML 55K
112: R88 Regulatory Requirements (Capital Measures) HTML 85K
(Details)
28: R89 Regulatory Requirements (Significant U.S. Bank HTML 125K
Operating Subsidiaries' Capital) (Details)
86: R90 Total Equity (Narrative) (Details) HTML 49K
82: R91 Total Equity (Preferred Stock Outstanding) HTML 78K
(Details)
103: R92 Total Equity (Preferred Stock) (Details) HTML 89K
81: R93 Total Equity (Components of Accumulated Other HTML 82K
Comprehensive Income (Loss)) (Details)
67: R94 Earnings Per Common Share (Calculation of Basic HTML 129K
and Diluted EPS) (Details)
108: R95 Earnings Per Common Share (Antidilutive Securities HTML 45K
Excluded from the Computation of Diluted EPS)
(Details)
65: R96 Interest Income and Interest Expense (Details) HTML 82K
40: R97 Employee Benefit Plans (Net Periodic Benefit HTML 56K
Expense) (Details)
74: R98 Income Taxes (Reconciliation of the Provision for HTML 42K
(Benefit from) Income Taxes and the U.S. Federal
Statutory Income Tax Rate) (Details)
69: R99 Segment and Geographic Information (Selected HTML 171K
Financial Information by Segments) (Details)
52: R100 Segment and Geographic Information (Assets by HTML 48K
Segments) (Details)
123: R101 Segment and Geographic Information (Net Revenues HTML 47K
by Geographic Information) (Details)
101: R102 Equity Method Investments (Narratives) (Details) HTML 51K
80: R103 Equity Method Investments (Investees) (Details) HTML 39K
23: R104 Subsequent Events (Details) HTML 70K
118: XML IDEA XML File -- Filing Summary XML 197K
19: EXCEL IDEA Workbook of Financial Reports XLSX 590K
48: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 7.12M
10: EX-101.INS XBRL Instance -- ms-20150331 XML 13.60M
12: EX-101.CAL XBRL Calculations -- ms-20150331_cal XML 597K
13: EX-101.DEF XBRL Definitions -- ms-20150331_def XML 3.62M
14: EX-101.LAB XBRL Labels -- ms-20150331_lab XML 6.55M
15: EX-101.PRE XBRL Presentations -- ms-20150331_pre XML 4.58M
11: EX-101.SCH XBRL Schema -- ms-20150331 XSD 679K
121: ZIP XBRL Zipped Folder -- 0001193125-15-169056-xbrl Zip 780K
Description of Operating Committee Medical Coverage
All members of the Operating Committee of Morgan Stanley (the “Company”) are eligible to participate in Company-sponsored health and insurance
benefit programs available in the relevant jurisdiction to similarly situated employees. Operating Committee members are also eligible to participate in Morgan Stanley’s Executive Health Program under which each Operating Committee member is
eligible to receive Company-funded access to a private primary care physician offering on-call services and an annual executive health care assessment. Operating Committee members who retire with three or more years of service with the Company are
eligible to receive retiree medical coverage for themselves and their eligible dependents paid by the Company. The Executive Health Program and retiree medical coverage for Operating Committee members may be amended or discontinued at any time,
including to curtail benefits for some or all covered individuals, to change the cost of coverage and to implement changes required by federal, state and local legislation.